Ultrasound-Based Approach to Delivering Potent Drugs Into Cancer Cells Shows Promise in Benchtop Experiments

Why It Matters

SonoPIN could overcome a major barrier to large‑molecule cancer drugs, enabling precise, low‑toxicity treatments and expanding the therapeutic landscape.

Key Takeaways

• SonoPIN uses ultrasound‑burst microbubbles for targeted drug entry
• Achieved 50% cancer cell death, 99% healthy cell viability
• Enables delivery of large PROTACs previously unable to cross membranes
• Microbubble targeting uses nucleic‑acid strands binding cancer‑specific receptors
• Future work includes mouse trials and potential gene‑editing delivery

Pulse Analysis

PROTACs have emerged as a powerful class of degraders capable of eliminating "undruggable" proteins, yet their clinical rollout stalls because the molecules are too bulky to cross cell membranes. Conventional delivery relies on endocytosis or carrier systems that often generate off‑target toxicity, especially when the target protein, such as BRD4, is also essential in normal tissue. The need for a non‑biological, size‑agnostic delivery vehicle has spurred research into physical methods like electroporation and sonoporation, but few have demonstrated both selectivity and efficiency at the cellular level.

The SonoPIN platform addresses this gap by pairing microbubbles—already approved as ultrasound contrast agents—with precisely tuned acoustic energy. When the bubbles collapse, they generate microjets and shock waves that perforate adjacent membranes for a few milliseconds, creating nanoscopic pores large enough for PROTACs to diffuse in. In Duke's benchtop experiments, fluorescently labeled PROTACs entered cancer cells seven times more efficiently than standard methods, resulting in half of the malignant cells undergoing apoptosis while virtually all healthy cells remained intact. The use of nucleic‑acid ligands on the bubble surface ensures that only cells expressing cancer‑specific receptors are exposed to the sonoporation effect, dramatically reducing collateral damage.

If the technology translates to animal models, it could reshape oncology pipelines by unlocking a suite of large‑molecule therapeutics—ranging from protein degraders to CRISPR‑based gene editors—that were previously dismissed due to delivery constraints. The mechanical nature of SonoPIN sidesteps immune clearance and may simplify regulatory pathways compared with viral or lipid nanoparticle carriers. Moreover, the ability to focus ultrasound on deep‑seated tumors offers a non‑invasive, repeatable treatment modality, positioning the platform as a potential cornerstone for precision medicine and a lucrative target for biotech investors.